Compare Alphabet Inc Class A (GOOGL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Novo Nordisk A/S — how do they compare? Alphabet Inc Class A trades at $345.57 (market cap $4.20T), while Novo Nordisk A/S trades at $45.81 (market cap $207.85B). The key difference: Alphabet Inc Class A is far larger — about 20.2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| GOOGL | NVO | |
|---|---|---|
Market Cap | $4.20T | $207.85B |
Sector | Media | Health |
52-Week High | $402.62 | $63.98 |
52-Week Low | $199.32 | $35.29 |
Enterprise Value | $4.09T | $222.55B |
Dividend Yield | 0.26% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $343.8, down 3.84% over 24 hours, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight robust profit growth, with net income reaching $132.17 billion in 2025. The stock faces near-term pressure from technical indicators but benefits from AI-driven revenue expansion and a consensus analyst price target of $426.28, suggesting significant upside potential.
The outlook remains positive due to solid earnings performance and AI investments, though risks include antitrust scrutiny and market volatility. With 85% of analysts rating it a buy, GOOGL offers long-term growth opportunities, but investors should monitor competitive and regulatory challenges that could impact valuation.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
